The first four authors contributed equally to this work Aberrant redox regulation occurs in immune and neurological pathologies, hence targeting the pathways involved in the regulation of the redox system could provide further insights into these diseases and open up new avenues for therapy. Soluble (s) CD30 is of key clinical importance in this respect, as its levels reflect the functionality of the CD30 receptor (CD30R), the specific lymphocyte receptor for thiol disulfide/oxidoreductase thioredoxin 1 (Trxl) which is known to regulate important immune and neurological processes. Increased levels of sCD30 appear to be a common element of oxidative stress, immunological alterations and neurological deficit, therefore these increases could be used as a clinical biomarker and target for therapy. We targeted sCD30 in our study of dendritic cell (DC) regulation of the T helper (Th) cell network in multiple sclerosis (MS) patients, as abnormalities in T regulatory (Treg)/ThllThl7 pathways contribute to the pathogenesis of this immunological/neurological disease. DC profiles in TreglThllTh2/Thl7-types of cytokine production in culture supernatants were used as they determine the type of Th differentiation. Our results show that sCD30 levels increase significantly in MS patients, reflecting the disruption in the regulation of the Treg/ThllThl7 cell network. A fall in the level of soluble CD30, induced by IFNpla therapy, opposed the increase of neurological deficit through increasing ILlO and TGFp levels, thus re-establishing network homeostasis but only when this was accompanied by an increase in ILl2p70 levels. Since ILl2p70 cytokine production is regulated by Trxl, our results indicate that redox system alterations may be the cause of IFNpla therapeutic inefficacy. We conclude that an increase in the level of ILlO, TGFp and ILl2p70 and a fall in the level of sCD30 represent a means of evaluating the clinical risk/benefit of IFNpla treatment.
signalling (4) . We believe that the up-and downregulation of sCD30 levels within physiological networks must be explored to target diagnostic and therapeutic intervention for stress-related degenerative diseases in immunological and neurological pathologies. Hence sCD30 could be used as a biomarker for evaluating clinical risk! benefit of IFN~1a treatment in MS patients. MS is a chronic immunological demyelinating CNS disorder, with the relapsing remitting/form (RR) comprising episodic relapses/remissions that may be partial or complete. IFN~1a therapy is only partially effective and not in all patients (5) , therefore more effective biomarkers and therapeutic targets are necessary. Currently, the only means of measuring treatment outcome is magnetic resonance (MR) (6) . Numerous studies have investigated the relationship between immunological parameters in serum (7) , urine (8) , cerebrospinal fluid (CSF) and clinical evidence of disease activity and progression in MS. However, consistent patterns of association with disease activity has not emerged. Distinct changes in peripheral regulatory cell network have been associated with neurological deficits in MS patients (9) , and it has been shown that abnormal Treg/Th 11Th17 pathways contribute to this disease pathogenesis (10) .
To our knowledge there is no literature reporting the role of CD30R or sCD30 in stress-related degenerative diseases, such as MS. Our previous studies indicate that the CD30RlsCD30 system mediates the homeostasis of Treg/ThllTh2 cell network (11) (12) (13) , highlighting a lack of this activity when sCD30 levels increase significantly or when CD30RlCD30L interaction and IL4/IFNy activities are blocked. In the context of the new Th network model, Treg/Th lITh2/Th17, the role of the Thl pathway would appear to antagonize Th 17 pathways, thus preventing immune-mediated brain tissue injury (14) . Classically immune responses have been classified into type 1 and type 2 responses controlled by the Th-subset Th 1, Th2 and Th3 (Treg) which is characterized by the production of TGF~(15). To be able to explain newly identified autoimmune mechanisms (14) a fourth Th population has been identified, Th17, producing ILl 7, IL6 and TNF cytokines. TGFB and IL6 interaction has been shown to induce Th17-autoimmunity progression by switching cell generation from Treg to Th17 (16) : Treg and Th17 cells generate from reciprocal developmental pathways: TGFB is the chief inducer of Tregs, but TGFB together with IL6 and IL23/ ILl2p40 promotes the generation of Th17 cells. It has also been reported that Thl and Th2 cytokines are required to reciprocally reduce Th 17 cells. On the basis of these new discoveries, Th 1 cells, long thought to mediate tissue damage, might only be involved in the initiation of tissue damage, without playing a decisive role. Hence a better understanding ofTreg/Thl/Th17 pathways could lead to significant developments in MS therapy (10) .
To assess how sCD30 levels influence the peripheral Treg/Th1/Th 17 immune regulatory cell network, we used the Th cytokine data-driven modelling approach, a system biology study method (17) . We measured levels of sCD30, sBcl2 and Treg/Thl/Th2/Th17 cytokines in immature (I)DC, DC and whole blood culture supernatants of RRMS patients. IDC and DC cytokine production profiles were used as they determine the functional type of Th differentiation (18): Thl-function ILl2p70, IFNy, IL2; Th2-function IL4, ILlO; Treg-function TGF~; Th17-function ILl2p40, IL6. sBcl2 is a cell survival biomarker; IL2, IFNy and ILl2p70 are cytokines which promote Thl functions (19) , promoting cell mediated immunity; IL4 and IL 10 are associated with Th2-like responses, and ILlO is a powerful inhibitor of IFNy and macrophages (20) ; TGF~is a Treg cytokine and a well-known immune modulating factor for IDC/DC/T regulating cell subsets (20) ; IL6 and IL23/ILl2p40 act like Th 17 (14, 21) and have anti-Th 1 functions (19) . Computational models were used to evaluate correlations between sCD30, sBcl2, Treg/ThllTh2/Th17 levels and neurological deficit (Expanded Disability Status Scale, EDSS) in IFN~1a treated and untreated patient groups.
MATERIALS AND METHODS

Patients
The studywas approvedby the local EthicsCommittee and all persons gave their informed consent prior to their inclusion in the study. We investigated 34 patients with clinicallydefinedRRMS admittedto the MS Center of the Department of Neurology of the University of L'Aquila. None of the patients had suffered an exacerbation in the 3 previous months, received corticosteroids in the month prior to entry, or immune suppressants in the 6 months leading up to the study. The Expanded Disability Status Scale (EDSS) and neurological examinations were carried out by neurologists ofthe MS Center ofthe Department of Neurology of the University of L'Aquila. EDSS was used to assess patient neurological deficit as MS is a chronic, lifelong disease and long-term deficit data should be evaluated. We considered the absence of clinical relapses of at least 3 months, a marker of disease inactivity. The treated group consisted of 3 men and 13 women, with a mean age±SE of 32.3±1.9 years and a mean EDSS score±SE of 2±0.3; all had been receiving IFN~la treatment [22 ug (4 patients) or 44 ug (12 patients)] subcutaneously thrice weekly for a mean period±SE of 27.5±1.4 months (range: 2 to 60 months)]. The untreated group of patients, matched for sex, age and EDSS score, consisted of 7 men and 11 women with a mean age±SE of 34.7±2.6 and a mean EDSS score±SE of 2±0.2. We also considered: time since last treatment (TLT): TLT was 1 day in 4 patients and 2 days in 12. Patient groups for TLT were matched for sex, age and EDSS score. This is a paired samples study: all parameters were determined for each patient sample.
Generation ofDCs from Monocytes
A sample of heparinized blood (20 IV/ml blood Liquemin Roche) was taken from each subject, and monocytes from PBMC samples were obtained by removing T cells, B cells, NK cells and granulocytes (if present), as previously described (13) . Monocytes were incubated in 24 well plates at a concentration of 200,000 cells per ml at 37°C in a humidified atmosphere of 5% CO 2 for 8 days and stimulated with 30 ng/ml of recombinant IL4 (Preprotech England, specific activity of >5xl0 6 U/mg), 30 ng/ml of recombinant GM CSF (Preprotech England, specific activity of> Ix 10 7 U/mg). On day 3, IL4 and GM CSF were added again and on day 6 IDCs were obtained.
To study the sCD30 functional pathways in immune resting conditions, IDC culture without stimuli were prepared. IDC cultures with stimuli were prepared with 100 ug/ml (Sigma) of LPS (obtaining LPS DC), 0.1 ng/ ml of recombinant human IFN~(IFN~DC) (Preprotech England, specific activity of >2xl0 7 U/mg), 1000U/ml of recombinant human IFNy (IFNy DC) (Collaborative Research incorporated, biomedical products, Bedford, Mass, specific activity 500.000 Units/IOO ul), After 2 days of culture the supernatant was removed from each well, centrifuged at 250 g and stored frozen in aliquots at -80°C until used.
Whole blood cell cultures
The whole blood culture method (22) was used to assess patient Treg/ThIlTh2/ThI7 type differentiation in peripheral blood since it reflects in vivo physiological conditions more accurately (23) . Briefly, a 15 ml sample of heparinized blood (22) 20 IV heparin/ml blood Liquemin Roche) was taken from each patient, and the samples, kept at room temperature, were used immediately. Venous blood was diluted 1:10 with RPMI 1640 medium, (Sigma, endotoxin tested), which was supplemented with 0.2 mM of L glutamine, 50 IV/ml of penicillin, 50 ug/ml streptomycin (Sigma) and 10% of human AB serum. Aliquots at lx10 6 cells were distributed in 12 mm polypropylene tubes. 10 ug/ml of PHA (Sigma) was used for stimulation as PHA is a non-specific T cell stimulant and provides more information on T cell contribution. After 3 days of culture the supernatant was removed and cytokine levels determined. The effect of adding heparin, which prevents clotting in whole blood cultures, was tested.
Cytokine detection
Cytokine levels and soluble molecules were determined using a solid phase sandwich ELISA method (13) . For intra assay precision, samples of known cytokine concentration were assayed in replicates of 10 to determine precision within an assay, the coefficient of variation was <10%. For inter assay precision, samples were assayed 30 times in multiple assays to determine precision between assays, the coefficient of variation was <10%. The ELISA assay sensitivity was: ILIO <lpg/ml, TGF~1 <1.9pg/ml, IL2 <lOpg/ml, IFNy <5pg/ml, IL6 <2pg/ml, (Euroclone), ILI2p40 <15pg/ml, lLI2p70 <0.5 pg/ml, IL4<0.13 pg/ml (R&D System), sCD30<0.5 U/ml, sBcl2<1 U/ml (Bender Medsystem).
Data analysis
The identification of real and accurate clinical biomarkers, therapeutic targets and physiological pathways can only be achieved through evaluations that take into account system biology characteristics. This entails a functional dynamic network study ofrelationships between and behavior of the multi components. The paradox is that the large data sets from systems biology evaluations can create confusion (24) and require the use of computational models for their interpretation (25) These so-called 'data driven computational models" based on experimental data, formalize a complex biological or experimental process mathematically, allowing multivariate biological measurements to become tractable to our intuition and often reveal new and unanticipated biological insights. Hence, in addition to the study of statistical differences using the Wilcoxon rank test for paired samples, the Mann Whitney U test or Student's t test as appropriate, data driven models of multivariate A: IDC sCD30 pathway regulation s 030 Values ofp:s 0.05 were considered significant. We used covariance method computational models which produce a matrix of covariances between parameters which can be positive or negative allowing a preliminary dynamic analysis of how network multi-components vary with respect to one another at any moment in time (Tables  III , IV and V) . The covariance method measures the linear associations between all parameters: if parameters increase or decrease at the same time, the covariance is positive whilst other changes are considered negative. Using principal component analysis (PCA) computational models we plotted the network of vectors obtained by mathematically analyzing the data matrix of covariances ( Fig. 1 ). In the 
analysis plots the vectors ofthe network interactions between parameters, showing the specific relationships: the angle between vectors is inversely proportional to the correlation between them, the same vector direction indicates a positive correlation, the opposite vector direction indicates a negative correlation, the length ofevery vector is proportional to the weight ofevery parameter inside the network.
plots obtained using the PCA method the angle between vectors is inversely proportional to the degree of correlation and covariance between vectors: the same vector direction indicates a positive correlation/covariance, the opposite vector direction indicates a negative correlation/covariance. This allows a visualization ofthe situation under examination and is an excellent method for capturing significance from systems biology evaluations (17) .
RESULTS
Levels ofsCD30, sBd2 molecules and cytokines in IDC, DC and PHA-whole-blood (T cells) culture supernatants in treated and untreated groups
These results are detailed in Tables I and II to resting immune conditions) and LPS DC supernatants (corresponding to activated immune conditions) were significantly higher in untreated patients in comparison to treated patients (Table I ).
In addition, levels of IL10 and IL 12p40 (Th2/Th 17), but not ILl2p70(Th I) were significantly higher in LPS DC supernatants than in IDC supernatants in untreated patients. The ILl2p70 increase in treated patients was the therapeutic effect of IFN~1a, opposing neural degeneration mechanisms since the increase of time from last treatment (TLT) and the neurologic deficit (EDSS parameter) were correlated to a decrease in IL12p70 levels (after LPS stimulus, r= -0.5 p=0.05 and r= -0.6 p=0.006 respectively). By analyzing the IDC and DC network data matrix for overall covariances (Tables III, IV) , we obtained a preliminary picture (Table V) of how a significant increase in sCD30 levels is a marker for i) change of DC profiles in Treg/Thl/Th17-type cytokines; ii) the disruption of the equilibrium in the DC regulation of the Treg/Th l/Thl ? cell network; iii) alterations in the immunological/neurological homeostasis leading to neurological deficit. In contrast, a significant fall in the level of sCD30 induced by therapeutic IFN~1a reflects the re-establishment of immunological network homeostasis and a blocking of neurological deficit.
We found that EDDS was negatively correlated to IDC TGF~(r= -0.7 p=0.02) and LPS-DC TGF~, IL12p70, IL12p40 (Treg, Thl, Th17, r= -0.5 p=0.03, r= -0.6 p=0.006 and r= -0.5 p=0.042 respectively), PHA-IL4 (Th2, r= -0.6 p= 0.03). When sCD30 levels increased, the levels of TGF~(Treg) in IDC and TGF~, IL12p70, IL12p40 (Treg, Thl, Th17) in LPS-DC also increased in the treated group (Table V) . An increase in sCD30 levels did not, on the other hand, correspond to an increase of TGF~in supernatants ofIDC (no Tregs in immune resting conditions) and IL12p70 in the LPS DC (Thl disruption in activation condition) in untreated patients (Table V) . These data suggest that the lowering of the sCD30 level in the treated patient cellular environment results in the re-establishment of Tregs (TGF~) under resting immunological conditions and Tregs, Thl and Th17 cells (TGF~, IL12p70, IL12p40) under activation conditions. Consequently the decrease of sCD30 levels in IDC and LPS DC supernatants, together with increases of TGF~levels in IDC and IL12p70 in LPS DC supernatants could be used as diagnostic laboratory markers for predicting the benefit of IFN~1a therapy. Fig. 1 summarizes the results ofthe PCAanalysis. IDC and DC regulation of the Th network in treated patients opposed EDSS increase differently to untreated patients and, as we hypothesized, sCD30 level is a marker for these changes. It is important to notice that the mechanisms that cause the changes are the same for both IDCs, DCs and the type of stimulus used for the DC activation and are directly affected by variations in sCD30 levels: an IFN~la induced decrease in sCD30 level first results in the re-establishment of Tregs (TGF~) and then Th network homeostasis, a balance which was absent in the untreated group.
Targeting of the immunological and neurological pathways of sCD30 and their homeostatic role in immune and neurological homeostasis
IDC sCD30 pathway regulation
One of the most important findings was that increases in TGF~IDC in treated patients correlated to neurological deficit decrease (the TGF~vector opposed EDSS vectors, Fig. IA) , determining network balance between IDC Th I and Th 17 pathways (the TGF~vector was positively correlated with both ILI2p70 and ILI2p40 vectors), a balance which was absent in the untreated patient group where the EDSS vector was positively correlated principally to the ILI2p70 vector and, hence, the Th l pathways. When looking at the functional influence of sCD30 levels (Fig. IA) , IDC sCD30 and IDC ILIO vectors opposed each other, underlining the fact that it was the therapeutic. IFN~Ia increase in LPS DC IL I0 levels which determined the fall in sCD30 levels in treated patients. In fact, it has been shown that IL-I 0 has a significant role in extracellular matrix formation by modulating expression of metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) which respectively induces and inhibits the release of sCD30 into the cell environment (26) . The increase in IL I0 levels and fall in sCD30 levels is therefore a change that could be targeted by immunological clinical investigations looking at IFN~I a treatment, especially as the increase of TLT was correlated to a decrease in patient ILIO (r= -0.5 p=0.044) and an increase in sCD30 levels (r=0.6 p=0.021). This suggestion is further supported by the discovery that IL10 suppressive activity and ILI OR signalling are impaired in MS patients: Tregs isolated from MS patients produce less IL I0 than those obtained from controls (27) . 
Under IDC+LPS ( LPS-DC) conditions
When LPS was used to stimulate IDC, an increase of sCD30 levels corresponded to an increase in the levels of TGFp (Treg) and IL12p70, IL12p40 (Thll Th17) cytokines in LPS-DC supernatants (Table  V) and an increase in the levels of IL12p70, IL6, IL12p40 (ThllThI7) in the PHA-supernatants in treated patients. This indicates that TGFp, IL12p70 and IL12p40 increases opposed EDSS increase by regulating the peripheral Thl/Thl7 network balance in treated patients. An increase in sCD30 levels, on the other hand, was found tocorrespond to an imbalance in the Th network patl1way in untreated patients (Table V) : in fact we found an increase in the levels of sBel2, the cell survival marker, without cytokine release in the DC supernatants, indicating a lack of LPS DC regulation of the peripheral Th network balance. These events highlight the fact that a lack of functional DCs is a key factor at''the basis ofthe pathological mechanisms responsible for MS. Furthermore, the fact that an increase of sCD30 levels does not correspond to an increase in any of the Th cytokines and that RCD30 is the receptor for Trx1, suggests that there may be alterations in the redox system resulting in a lack of signal translation from the membrane receptor to the nueleus. Fig. IB summarizes the results of the PCA analysis. We noted that TGFp, IL12p70 and IL12p40 vectors oppose increase in EDSS vectors and that the sCD30 vector was positively correlated principally to the TGFp vector in treated patients. The latter result suggesting once again that the IFNplainduced fall in sCD30 levels initially results in the re-establishment of Tregs (TGFP) and then in Th network homeostasis.
Under IDC+IFNP (IFNP-DC) conditions
The results of the analyses in relation to in vitro activation of IDC by IFNp stimulus are given in Tables III, IV and V. In treated patients, an increase of sCD30 levels coincided with an increase in sBel2, but also in TGFp (Treg) and IL12p70, IL12p40 (ThllThI7) levels and an increase in the levels of PHA IL12p70 (Thl), IL4 (Th2), and I  2  3  4 II  2  3  4  II  2  3  4 II  2  3  4  II  2  3  4 II  2 IL6, ILl2p40 (ThI7). Therefore, an sCD30 level increase is correlated to an increase in Tregs, and Thl/Th2/ThI7 network balance in treated patients. In untreated patients, an increase of sCD30 levels did not coincide with an increase of DC Tregs (no TGFĩ ncrease) or the homeostasis of the DC Thl/Th17 network (no increase ofILl2p70). Fig. 1C summarizes the results of the PCA analysis and we found once again that i) sCD30 and TGF~, ILl2p70, ILl2p40 vectors oppose EDSS vector increase and, ii) the sCD30 vector was positively correlated to the TGF~vector in treated patients, suggesting once again that the JFN~1a induced fall in sCD30 levels initially results in the re-establishment of Tregs (TGF~) and then in Th network homeostasis.
Under IDC+lFNy (IFNy-DC) conditions
An increase of sCD30 levels is again responsible for determining TGF~(Treg) and
ILl2p70, ILI2p40(Thl/Th17) network balance, correlated to EDSS decrease, in treated patients (Table V ). An increase of sCD30 levels in untreated patients, on the other hand, corresponded to an increase in the levels of sBcl2 without cytokine release, indicating a lack of DC regulation of the peripheral Th network balance. Fig. ID summarizes the results of the PCA analysis and we were able to draw the same conclusions mentioned above for Fig. 1C .
DISCUSSION
The recent discovery that CD30R is the lymphocyte receptor for Trxl (2), a thiol-disulfide oxidoreductase which regulates important immune and neurological processes (3), opens up new perspectives for targeted therapeutic intervention in stress-related degenerative diseases. Hence, sCD30 is of key clinical importance as its levels reflect the functionality ofCD30R (4).
Our overall results (Fig. 2) indicate that the up-and down-regulation of sCD30 levels within physiological ranges lead to homeostasis in immunological and neurological pathways. However, when, as in MS patients, there is a significant increase of sCD30 levels, this leads to and is marker for immunological alterations and neurological deficit and could therefore be used as a clinical biomarker and target for therapy. Our results show that sCD30 pathways control immunological and neurological system homeostasis by regulating the type of Th differentiation through the cytokine profiles of IDCs and DCs.
When sCD30 levels increase significantly, as in untreated patients, alterations are produced in the homeostasis of the immune system through the disruption of IDC/DC pathway regulation of the Treg/Th l/Thl ? cell network, leading to EDSS increase (Figs. 1, 2) . IFN~la, on the other hand, lowers sCD30 levels, re-establishes homeostasis by restoring the IDC/DC regulation of the Treg/ Thl/Th17 cell network and opposes neurological deficit increases. Dendritic cells (DCs) are major professional APCs that initiate and modulate immune response by inducing ThO differentiation (28) . Various DC-derived factors that induce Th cell polarization have been identified, including the Thl cell-polarizing cytokines IL-12 and IL-23 and the Th2/regulatory T cell-polarizing cytokines IL-IO and TGF-~ (28) . It has been shown that DCs not only produce IL-12 and IL-23 but also express high levels oftheir receptors, indicating an autocrine regulatory loop (29) . However, IFN~la was only partially successful in restoring physiological pathways in vivo when there was Thl (IL2p70) suppression. The explanation for this lies in the fact that DC TGF~and ILl2p70 production are normally involved in in vivo mechanisms leading to the elimination of self-reactive cells (30) . The destruction of self-reactive cells and prevention of EDSS neurologic deficit are mediated by DCs inducing TGF~IFNy production, and ILl2p70 is the principal IFNy inducer. Consequently, the increase in IDC and LPS DC ILl 0 levels, together with a fall in sCD30 levels and an increase in LPS DC TGF~and ILl2p70 levels, are biomarkers for immunological homeostasis and for evaluating the clinical risk! benefit of IFN~1a treatment. It is important to note that the mechanisms that cause the changes in immunological/neurological pathways in untreated and treated patients are the same and are independent of IDC or DC conditions or the type of stimulus used for DC activation. However, these mechanisms are directly affected by variations in sCD30 levels; an IFN~la therapy-induced decrease in sCD30 levels is initially responsible for the re-establishment ofTregs (TGF~) and successively in Th network homeostasis, a balance which was absent in the untreated group where EDSS increase was positively correlated to a rise in sCD30 levels without TGF~(Treg) and to Th network alterations. Furthermore, our results suggest that thioredoxin 1 redox system alterations may be the cause of IFN~1a therapeutic inefficacy since IFN~1a was only partially successful in restoring physiological pathways in vivo when there was Thl IL2p70 suppression, and ILl2p70 cytokine production is regulated by Trx1 (31) .
To sum up, our results uphold prior findings that the lack of functional DCs is the key to immune pathological mechanisms at the basis of MS. This study indirectly supports the hypothesis that an increase in sCD30 levels is a biomarker for alterations in the redox system. Consequently, sCD30 is a marker of immunological and neurological homeostasis and this newly identified function must now be used to develop new strategies in clinical investigations and for the therapeutic treatment of immunological and neurological diseases. The next step is to establish a direct support of our hypothesis that an increase in sCD30 levels is a biomarker for alterations in the redox system, by studying how Trx1 and sCD30 regulate redox/neurological homeostasis and whether this regulation is indirect through the peripheral immune system or directly through the central nervous system. Indeed, i) Trxl from IFNyactivated macrophages is a potent neurotrophic factor for central cholinergic neurons (32) and ii) critical roles ofTrx 1 in nerve growth factor mediated signal transduction were found (5) . The discovery of the role of sCD30 at this level is very exciting, especially in light of the fact that sCD30 increases have been found in various immune and neurological pathologies (33) (34) (35) . Being able to manipulate the role of sCD30 may well represent a non-invasive tool for these pathological conditions and an instrument for redirecting the immune systems towards a more appropriate physiological response.
